VANGUARD GROUP INC - SAGE THERAPEUTICS INC ownership

SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 194 filers reported holding SAGE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.

Quarter-by-quarter ownership
VANGUARD GROUP INC ownership history of SAGE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$107,180,681
-54.7%
5,208,002
+3.5%
0.00%
-50.0%
Q2 2023$236,625,188
+13.2%
5,032,437
+1.1%
0.01%
+20.0%
Q1 2023$208,951,191
+12.1%
4,979,771
+1.9%
0.01%0.0%
Q4 2022$186,334,954
-0.6%
4,885,552
+2.0%
0.01%
-16.7%
Q3 2022$187,492,000
+22.4%
4,787,865
+0.9%
0.01%
+50.0%
Q2 2022$153,194,000
+0.1%
4,742,839
+2.5%
0.00%0.0%
Q1 2022$153,088,000
-21.4%
4,625,003
+1.0%
0.00%0.0%
Q4 2021$194,758,000
-9.0%
4,578,241
-5.2%
0.00%
-20.0%
Q3 2021$214,073,000
-21.9%
4,831,269
+0.1%
0.01%
-28.6%
Q2 2021$274,097,000
-23.0%
4,824,810
+1.4%
0.01%
-30.0%
Q1 2021$356,139,000
-10.5%
4,758,038
+3.5%
0.01%
-16.7%
Q4 2020$397,870,000
+44.0%
4,599,115
+1.7%
0.01%
+33.3%
Q3 2020$276,290,000
+40.4%
4,520,440
-4.5%
0.01%
+28.6%
Q2 2020$196,799,000
+41.7%
4,733,032
-2.1%
0.01%
+16.7%
Q1 2020$138,857,000
-59.0%
4,834,852
+3.1%
0.01%
-50.0%
Q4 2019$338,627,000
-48.0%
4,690,782
+1.0%
0.01%
-50.0%
Q3 2019$651,824,000
-22.7%
4,646,261
+0.9%
0.02%
-25.0%
Q2 2019$843,392,000
+16.1%
4,606,430
+0.9%
0.03%
+14.3%
Q1 2019$726,174,000
+88.5%
4,565,699
+13.5%
0.03%
+64.7%
Q4 2018$385,312,000
-33.2%
4,022,470
-1.6%
0.02%
-26.1%
Q3 2018$577,121,000
-3.6%
4,085,812
+6.9%
0.02%
-8.0%
Q2 2018$598,386,000
-1.3%
3,822,822
+1.6%
0.02%
-7.4%
Q1 2018$606,073,000
+9.8%
3,762,784
+12.2%
0.03%
+12.5%
Q4 2017$552,182,000
+213.2%
3,352,445
+18.5%
0.02%
+200.0%
Q3 2017$176,325,000
-19.5%
2,830,252
+2.9%
0.01%
-27.3%
Q2 2017$219,006,000
+14.5%
2,749,954
+2.2%
0.01%
+10.0%
Q1 2017$191,269,000
+54.2%
2,691,275
+10.8%
0.01%
+42.9%
Q4 2016$124,052,000
+17.3%
2,429,516
+5.8%
0.01%
+16.7%
Q3 2016$105,767,000
+101.4%
2,296,767
+31.8%
0.01%
+100.0%
Q2 2016$52,503,000
+1.0%
1,742,561
+7.5%
0.00%0.0%
Q1 2016$51,981,000
-33.1%
1,621,375
+21.7%
0.00%
-40.0%
Q4 2015$77,654,000
+62.0%
1,331,977
+17.6%
0.01%
+150.0%
Q3 2015$47,935,000
-23.7%
1,132,661
+31.7%
0.00%
-50.0%
Q2 2015$62,795,000
+100.7%
860,189
+38.1%
0.00%
+100.0%
Q1 2015$31,290,000
+283.8%
622,943
+179.7%
0.00%
+100.0%
Q4 2014$8,152,000
+696.1%
222,745
+584.8%
0.00%
Q3 2014$1,024,00032,5250.00%
Other shareholders
SAGE THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
RTW INVESTMENTS, LP 5,149,482$105,976,3402.24%
Palo Alto Investors LP 1,005,776$20,698,8701.96%
Boxer Capital, LLC 1,094,000$22,514,5201.20%
Bellevue Group AG 3,513,351$72,304,7641.16%
PDT Partners, LLC 181,625$3,737,8430.47%
EASTERLY INVESTMENT PARTNERS LLC 195,643$4,026,3330.44%
Harvest Investment Services, LLC 30,302$623,6150.40%
Simplify Asset Management Inc. 120,030$2,470,2170.28%
SAMLYN CAPITAL, LLC 739,867$15,226,4630.25%
CAXTON ASSOCIATES LP 68,035$1,400,1600.19%
View complete list of SAGE THERAPEUTICS INC shareholders